Treatment Outcome of Combination Therapy Including Clarithromycin for Mycobacterium Avium Complex Pulmonary Disease

Korean Journal of Internal Medicine

Volumn 26, Issue 1, 2011, Pages 55-59

  Kim, Eun Young ^a   Chi, Su Young ^a   Oh, In Jae ^a   Kim, Kyu Sik ^a   Kim, Yu Il ^a   Lim, Sung Chul ^a   Kim, Young Chul ^a   Kwon, Yong Soo ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Clarithromycin; Mycobacterium avium complex; Treatment outcome

Indexed keywords

CLARITHROMYCIN; ETHAMBUTOL; RIFAMPICIN; STREPTOMYCIN; ANTIINFECTIVE AGENT;

ACID FAST BACTERIUM; ADULT; AGED; ANOREXIA; ANTIBIOTIC THERAPY; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BRONCHIECTASIS; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMOPTYSIS; HUMAN; KOREA; LUNG FIBROSIS; LUNG INFECTION; MALE; MEDICAL RECORD REVIEW; NAUSEA; OPTIC NEURITIS; OUTCOME ASSESSMENT; RELAPSE; SEROCONVERSION; SPUTUM CULTURE; SPUTUM SMEAR; THORAX RADIOGRAPHY; TREATMENT DURATION; DRUG COMBINATION; LUNG DISEASE; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79953282644     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2011.26.1.54     Document Type: Article

References (22)

1. Koh WJ, Kwon OJ, Jeon K, et al. Clinical significance of nontu-berculous mycobacteria isolated from respiratory specimens in Korea. Chest 2006; 129: 341-348.
2. Lee JY, Choi HJ, Lee H, et al. Recovery rate and characteristics of nontuberculous mycobacterial isolates in a university hospital in Korea. Tuberc Respir Dis 2005; 58: 385-391.
3. Choi SP, Lee BK, Min JH, Kim JH. Pathogenic classification and clinical characteristics of nontuberculous mycobacterial pul-monary disease in a National Tuberculosis Hospital. Tuberc Respir Dis 2005; 59: 606-612.
4. Koh WJ, Kwon OJ. Diagnosis and treatment of nontuberculous mycobacterial lung disease. Korean J Med 2008; 74: 120-131.
5. Jeon K, Koh WJ, Kwon OJ, et al. Usefulness of bronchoscopy for the diagnosis of nontuberculous mycobacterial pulmonary disease. Tuberc Respir Dis 2004; 57: 242-249.
6. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
7. Korean Academy of Tuberculosis and Respiratory Disease. Guidelines for the management of tuberculosis. Seoul: Korean Academy of Tuberculosis and Respiratory Disease, 2005.
8. Koh WJ, Kwon OJ, Kang EH, et al. Treatment of Mycobacterium avium complex (MAC) pulmonary disease. Tuberc Respir Dis 2004; 57: 234-241.
9. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000; 161(4 Pt 1): 1376-1395.
10. Kee SJ, Kim SM, Kim SH, et al. Multiplex PCR assay for identifi cation of mycobacterial species isolated from liquid cultures. Chonnam Med J 2009; 45: 19-26.
11. Dautzenberg B, Piperno D, Diot P, Truffot-Pernot C, Chauvin JP. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS: Clarithromycin Study Group of France. Chest 1995; 107: 1035-1040.
12. Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first 50 patients. Am J Respir Crit Care Med 1996; 153(6 Pt 1): 1766-1772.
13. Field SK, Fisher D, Cowie RL. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest 2004; 126: 566-581.
14. Wallace RJ Jr, Brown BA, Griffith DE. Drug intolerance to high- dose clarithromycin among elderly patients. Diagn Microbiol Infect Dis 1993; 16: 215 221.
15. Carter G, Young LS, Bermudez LE. A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation. Antimicrob Agents Chemother 2004; 48: 4907-4910.
16. Hasegawa N, Nishimura T, Watabnabe M, et al. Concentrations of clarithromycin and active metabolite in the epithelial lining fluid of patients with Mycobacterium avium complex pulmonary disease. Pulm Pharmacol Ther 2009; 22: 190-193.
17. Kobashi Y, Matsushima T. The microbiological and clinical effects of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease in Japan - including a follow-up study. Respiration 2007; 74: 394-400.
18. Hasegawa N, Nishimura T, Ohtani S, et al. Therapeutic effects of various initial combinations of chemotherapy including clarithromycin against Mycobacterium avium complex pulmonary disease. Chest 2009; 136: 1569-1575.
19. Fujikane T, Fujiuchi S, Yamazaki Y, et al. Efficacy and outcomes of clarithromycin treatment for pulmonary MAC disease. Int J Tuberc Lung Dis 2005; 9: 1281-1287.
20. Tanaka E, Kimoto T, Tsuyuguchi K, et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1999; 160: 866-872.
21. Lam PK, Griffith DE, Aksamit TR, et al. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006; 173: 1283-1289.
22. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med 1997; 156(2 Pt 2): S1-S25.